Literature DB >> 18785757

Fitting yeast and mammalian prion aggregation kinetic data with the Finke-Watzky two-step model of nucleation and autocatalytic growth.

Murielle A Watzky1, Aimee M Morris, Eric D Ross, Richard G Finke.   

Abstract

Recently, we reported 14 amyloid protein aggregation kinetic data sets that were fit using the "Ockham's razor"/minimalistic Finke-Watzky (F-W) two-step model of slow nucleation (A --> B, rate constant k 1) and fast autocatalytic growth (A + B --> 2B, rate constant k 2), yielding quantitative (average) rate constants for nucleation ( k 1) and growth ( k 2), where A is the monomeric protein and B is the polymeric protein [Morris, A. M., et al. (2008) Biochemistry 47, 2413-2427]. Herein, we apply the F-W model to 27 representative prion aggregation kinetic data sets obtained from the literature. Each prion data set was successfully fit with the F-W model, including three different yeast prion proteins (Sup35p, Ure2p, and Rnq1p) as well as mouse and human prions. These fits yield the first quantitative rate constants for the steps of nucleation and growth in prion aggregation. Examination of a Sup35p system shows that the same rate constants are obtained for nucleation and for growth within experimental error, regardless of which of six physical methods was used, a unique set of important control experiments in the protein aggregation literature. Also provided herein are analyses of several factors influencing the aggregation of prions such as glutamine/asparagine rich regions and the number of oligopeptide repeats in the prion domain. Where possible, verification or refutation of previous correlations to glutamine/asparagine regions, or the number of repeat sequences, in literature aggregation kinetics is given in light of the quantitative rate constants obtained herein for nucleation and growth during prion aggregation. The F-W model is then contrasted to four literature mechanisms that address the molecular picture of prion transmission and propagation. Key limitations of the F-W model are listed to prevent overinterpretation of the data being analyzed, limitations that derive ultimately from the model's simplicity. Finally, possible avenues of future research are suggested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785757     DOI: 10.1021/bi800726m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  A variational model for oligomer-formation process of GNNQQNY peptide from yeast prion protein Sup35.

Authors:  Xianghong Qi; Liu Hong; Yang Zhang
Journal:  Biophys J       Date:  2012-02-07       Impact factor: 4.033

2.  A generic crystallization-like model that describes the kinetics of amyloid fibril formation.

Authors:  Rosa Crespo; Fernando A Rocha; Ana M Damas; Pedro M Martins
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

3.  Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics.

Authors:  A Singla; R Bansal; Varsha Joshi; Anurag S Rathore
Journal:  AAPS J       Date:  2016-02-22       Impact factor: 4.009

4.  Mechanisms of aggregation and fibril formation of the amyloidogenic N-terminal fragment of apolipoprotein A-I.

Authors:  Chiharu Mizuguchi; Miho Nakagawa; Norihiro Namba; Misae Sakai; Naoko Kurimitsu; Ayane Suzuki; Kaho Fujita; Sayaka Horiuchi; Teruhiko Baba; Takashi Ohgita; Kazuchika Nishitsuji; Hiroyuki Saito
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

5.  Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments.

Authors:  Samuel I A Cohen; Michele Vendruscolo; Mark E Welland; Christopher M Dobson; Eugene M Terentjev; Tuomas P J Knowles
Journal:  J Chem Phys       Date:  2011-08-14       Impact factor: 3.488

6.  Competition between primary nucleation and autocatalysis in amyloid fibril self-assembly.

Authors:  Kym Eden; Ryan Morris; Jay Gillam; Cait E MacPhee; Rosalind J Allen
Journal:  Biophys J       Date:  2015-02-03       Impact factor: 4.033

7.  Relationship between prion propensity and the rates of individual molecular steps of fibril assembly.

Authors:  Yi-Qian Wang; Alexander K Buell; Xin-Yu Wang; Mark E Welland; Christopher M Dobson; Tuomas P J Knowles; Sarah Perrett
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

8.  A mechanistic model for amorphous protein aggregation of immunoglobulin-like domains.

Authors:  Madeleine B Borgia; Adrian A Nickson; Jane Clarke; Michael J Hounslow
Journal:  J Am Chem Soc       Date:  2013-04-18       Impact factor: 15.419

9.  High-throughput thermal stability analysis of a monoclonal antibody by attenuated total reflection FT-IR spectroscopic imaging.

Authors:  Maxime Boulet-Audet; Bernadette Byrne; Sergei G Kazarian
Journal:  Anal Chem       Date:  2014-09-26       Impact factor: 6.986

10.  Essential Oils May Lead α-Synuclein towards Toxic Fibrils Formation.

Authors:  Dina Morshedi; Mahour Nasouti
Journal:  Parkinsons Dis       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.